Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 29, 2015 7:32 AM ET


Company Overview of Enzo Life Sciences, Inc.

Company Overview

Enzo Life Sciences, Inc. researches, develops, manufactures, licenses, and markets life science research reagents. It offers proteins, antibodies, peptides, small molecules, labeling probes dyes, ELISA kits, natural products, neurochemicals, enzymes, and inhibitors to provide life science researchers tools for target identification/validation, high content and gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. The company also provides DNA, RNA, and protein quantification assays; genomics and general molecular biology tools; molecular labels and probes; compound libraries; and enzymatic, protein, and immunological assays. In addition,...

10 Executive Boulevard

Farmingdale, NY 11735

United States

Founded in 1976





Key Executives for Enzo Life Sciences, Inc.

Age: 56
President of Enzo Biochem Inc
Age: 64
Head of Global Technology Business Development
Chief Scientific Officer
Global Head of Marketing
Compensation as of Fiscal Year 2014.

Enzo Life Sciences, Inc. Key Developments

Enzo Life Sciences, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014

Enzo Life Sciences, Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported that product revenues continued to grow as a result of the increased focus on fewer but higher margin products, increasing 4%, to $8.0 million. Operating income totaled $1.6 million, compared to operating income of $1.4 million in the prior year. EBITDA declined to $1.7 million, compared to $2.3 million, a year ago primarily due to lower royalties.

Enzo Biochem Announces Settlement Agreement with PerkinElmer

Enzo Biochem, Inc. along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc. with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer, Inc. has agreed to pay $7,000,000 in escrow in settlement pursuant to the Agreement.

Andrew Whiteley Resigns as Chief Operating Officer for Enzo Life Sciences

Enzo Biochem Inc. announced that Andrew Whiteley is no longer with the company in the role as Chief Operating Officer for Enzo Life Sciences.

Similar Private Companies By Industry

Company Name Region
Millennium Life Sciences, Inc. United States
ZetaRx Biosciences, Inc. United States
Phytera, Inc. United States
RhoQ, Inc. United States
Reviva Pharmaceuticals Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enzo Life Sciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at